Pfizer insists that the discontinuation of the Phase II study was due to recruitment difficulties and was not linked to maplirpacept’s safety or efficacy.

Pfizer has terminated a Phase II study of its CD47 immune checkpoint inhibitor, maplirpacept, due to low recruitment. In an update on ClinicalTrials.gov, the company stated the study (NCT05626322) was ...

CD47 is a protein which triggers SIRPα on macrophages to inhibit their function and lower the anti-tumor immune response. Therapeutic treatments blocking CD47 has been tested but result in toxicities ...

Dublin, Aug. 23, 2022 (GLOBE NEWSWIRE) -- The "Global CD47 Inhibitor Drug Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The global CD47 market ...

CD47 ligation by immobilized monoclonal antibody against CD47 or by its natural ligand TSP induced, after 18 hours, features typical of apoptosis : cell shrinkage (reduction in forward scatter and ...

“CD47 expression in CRC was associated with the activation of several oncogenic pathways and an immune-engaged TME. Our findings may provide valuable information for considering new ...

Dublin, Dec. 15, 2021 (GLOBE NEWSWIRE) -- The "CD47 Targeting Therapeutics Market Industry Trends and Global Forecasts, 2021-2035" report has been added to ResearchAndMarkets.com's offering.

CD47 is a cell surface glycoprotein expressed on a wide variety of cells. It is a receptor for thrombospondin-1 and a counter-receptor for the signal regulatory protein-α (SIRPα).

While CD47 supports mesenchymal progenitor cell proliferation, its absence paradoxically promotes endothelial cell growth. This delicate balance is key to effective fracture repair, ...

Here’s one story the news media may have gotten right. Stanford researchers, led by pathologist Dr. Irving Weissman, have been conducting studies in mice—introducing antibodies to a protein known as ...

The company bought a spot in the CD47 race in 2020, when it paid I-Mab $180 million upfront and put up $1.74 billion in milestones for the ex-China rights to lemzoparlimab.